The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Open accessAbstract
The kinetics and nature of equilibrium binding were used to characterize the molecular interaction of the anthranilic acid derivative [3 H]‐XR9576 with the multidrug resistance P‐glycoprotein (P‐gp). XR9576 displayed specific high‐affinity binding to P‐gp (B max=275 pmol mg−1, Kd=5.1 n M). The transport substrates [3 H]‐vinblastine and [3 H]‐paclitaxel displayed 4 fold and 20 fold lower affinity respectively for P‐gp. The duration of action of XR9576 with P‐gp was increased in comparison to that of vinblastine which displayed a slower rate of association and a faster dissociation rate. The relative affinities of several modulators and transport substrates to interact with P‐gp were determined from displacement drug equilibrium binding assays. Vinblastine and paclitaxel could only fractionally displace [3 H]‐XR9576 binding, displaying Ki values significantly different from their measured Kd values. This suggests a non‐competitive interaction between XR9576 and the P‐gp substrates vinblastine and paclitaxel. XR9576 was shown to be a potent modulator of P‐gp mediated [3 H]‐vinblastine and [3 H]‐paclitaxel transport as it increased the steady‐state accumulation of these cytotoxics in CH r B30 cells to levels observed in non‐P‐gp‐expressing AuxB1 cells (EC 50=487±50 n M). This inhibition of drug transport is not mediated through competition for transport since [3 H]‐XR9576 accumulation was not influenced by P‐gp expression or function. These results demonstrate that the P‐gp modulator XR9576 exhibits greater selectivity, duration of inhibition and potency of interaction with this transporter than any other reported modulators. Several lines of evidence suggest that XR9576 inhibits P‐gp function by binding at a site which is distinct from the site of interaction of transport substrates. The two sites may be classified as serving modulatory or transport functions. British Journal of Pharmacology (1999) 128, 403–411; doi:10.1038/sj.bjp.0702807
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
DeLean, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,374
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Enzyme changes in neonatal skeletal muscle: effect of thyroid deficiency
Baldwin, K. M., Hooker, A. M., Campbell, P. J., & Lewis, R. E. (1978) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1978.235.3.c97 · Cited by 1,118
Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines
Kartner, N., Riordan, J. R., & Ling, V. (1983) · Science · doi:10.1126/science.6137059 · Cited by 991
Pharmacologic Analysis of Drug Receptor Interaction
Kenakin, K. T. (1988) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198803000-00029 · Cited by 927
Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G., Taylor, C. W., Miller, T. P., & Salmon, S. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.415 · Cited by 556
Hyafil, F., Pauwels-Vergely, C., Vignaud, P. D., & Grand‐Perret, T. (1993) · PubMed · Cited by 525
Chifflet, S., Torriglia, A., Chiesa, R., & Tolosa, S. (1988) · Analytical Biochemistry · doi:10.1016/0003-2697(88)90002-4 · Cited by 489
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells.
Horio, M., Gottesman, M. M., & Pastan, I. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.10.3580 · Cited by 476
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance
Sharom, F. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.1.105 · Cited by 973
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Kathawala, R. J., Gupta, P., Ashby, C. R., & Chen, Z.-S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.11.002 · Cited by 777
ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
Eckford, P. D. W., & Sharom, F. J. (2009) · Chemical Reviews · doi:10.1021/cr9000226 · Cited by 597
Quinoline as a Privileged Scaffold in Cancer Drug Discovery
R. Solomon, V., & Lee, H. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795328382 · Cited by 581
Communication between Multiple Drug Binding Sites on P-glycoprotein
Martin, C., Berridge, G., Higgins, C. F., Mistry, P., Charlton, P., & Callaghan, R. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12429-7 · Cited by 418
Self-citationInhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
(2001) · PubMed · Cited by 350
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Fox, E., & Bates, S. E. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.447 · Cited by 350
Krajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
Structure and function of efflux pumps that confer resistance to drugs
BORGES-WALMSLEY, M. I., McKEEGAN, K. S., & WALMSLEY, A. R. (2003) · Biochemical Journal · doi:10.1042/bj20020957 · Cited by 278
Wu, C., Calcagno, A. M., & Ambudkar, S. V. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801020093 · Cited by 259
Ward, A. B., Szewczyk, P., Grimard, V., Lee, C.-W., Martinez, L., Doshi, R., Caya, A., Villaluz, M., Pardon, E., Cregger, C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309275110 · Cited by 256
Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
Shukla, S., Wu, C.-P., & Ambudkar, S. V. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.205 · Cited by 253
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Pariante, C. M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A. H., & Kerwin, R. W. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704368 · Cited by 159
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
Metadata
- Authors
- Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1999-09
- Volume
- 128
- Issue
- 2
- Pages
- 403-411
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2024250662
- Cited by
- 258
- References
- 23
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.